Education
About Us
Working with TipRanks
Follow Us
Scandinavian ChemoTech AB Class B (SE:CMOTEC.B)
:CMOTEC.B
Top Page
Scandinavian ChemoTech AB Class B
(Frankfurt:CMOTEC.B)
Select Model
Select Model
Rating:54Neutral
Price Target:―
Scandinavian ChemoTech AB shows strong revenue growth and has a solid financial structure with no debt, reducing financial risk. However, persistent operational inefficiencies and ongoing cash burn weigh on profitability and valuation. Technical indicators point to short-term momentum, but potential overbought conditions warrant caution. Overall, while there are promising aspects, significant challenges in achieving sustainable profitability remain.
Scandinavian ChemoTech AB Class B (CMOTEC.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr116.25M
Dividend YieldN/A
Average Volume (3M)129.34K
Price to Earnings (P/E)―
Beta (1Y)0.39
Revenue Growth113.59%
EPS Growth54.12%
CountrySE
Employees3
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding21,692,312
10 Day Avg. Volume104,833
30 Day Avg. Volume129,338
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)6.99
Price to Sales (P/S)6.36
P/FCF Ratio-3.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Scandinavian ChemoTech AB Class B Business Overview & Revenue Model
Company DescriptionScandinavian ChemoTech AB Class B (CMOTEC.B) is a Swedish medical technology company that operates within the healthcare sector, focusing on developing innovative treatments for cancer. The company specializes in the research, development, and commercialization of tumor-specific electroporation techniques aimed at improving the effectiveness of cancer treatment. With a commitment to enhancing patient outcomes, Scandinavian ChemoTech provides advanced medical solutions that leverage cutting-edge technology to address unmet needs in oncology care.
How the Company Makes MoneyScandinavian ChemoTech AB generates revenue primarily through the sale and licensing of its proprietary medical technologies and devices designed for cancer treatment. The company's revenue streams include direct sales of its electroporation equipment to healthcare providers and hospitals, as well as potential licensing agreements with other medical technology companies. Additionally, Scandinavian ChemoTech may engage in strategic partnerships or collaborations that contribute to its earnings, leveraging its specialized expertise in electroporation to expand its market reach and enhance its product offerings. These revenue-generating activities are supported by ongoing research and development investments, aimed at continuously improving the efficacy and safety of their treatments.
Scandinavian ChemoTech AB Class B Financial Statement Overview
Summary
Scandinavian ChemoTech AB shows promising revenue growth but continues to face challenges with profitability and cash flow management. The company's financial structure benefits from a lack of debt, reducing financial risk, but operational improvements are needed to achieve sustainable profitability. Continued investment and strategic adjustments may be required to address ongoing losses and cash outflows.Income Statement
The company demonstrates significant revenue growth, with a sharp increase from SEK 473,000 in 2022 to SEK 6,566,000 in 2024. However, the company has consistently reported negative net income, resulting in negative net profit margins, indicating ongoing losses. Gross profit margins have improved, but the EBIT and EBITDA margins remain negative, reflecting operational inefficiencies.45
Neutral
Balance Sheet
The balance sheet shows an improvement in the equity ratio, as stockholders' equity remains positive and there is no debt on the balance sheet as of 2024. The return on equity is negative due to persistent losses, but the absence of debt reduces financial risk. The company has a reasonable buffer of cash and short-term investments relative to its liabilities.55
Neutral
Cash Flow
The company's free cash flow has improved from highly negative figures in previous years but remains negative, indicating ongoing cash burn. Operating cash flows have been negative, but financing activities have provided necessary liquidity. The cash flow to net income ratios are negative due to the negative net income and operating cash flow.50
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 9.85M | 6.57M | 2.82M | 473.00K | 49.00K | 131.00K |
| Gross Profit | 7.69M | 4.78M | 1.66M | -55.00K | 323.00K | -14.00K |
| EBITDA | -7.46M | -12.38M | -19.58M | -20.81M | -17.03M | -10.77M |
| Net Income | -10.68M | -13.72M | -21.09M | -22.75M | -17.74M | -11.66M |
Balance Sheet | ||||||
| Total Assets | 12.48M | 13.38M | 14.87M | 21.70M | 25.81M | 15.99M |
| Cash, Cash Equivalents and Short-Term Investments | 517.00K | 949.00K | 923.00K | 5.85M | 8.68M | 1.49M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 53.00K | 2.71M |
| Total Liabilities | 10.29M | 7.40M | 3.84M | 7.71M | 1.89M | 6.75M |
| Stockholders Equity | 2.19M | 5.98M | 11.03M | 13.99M | 23.92M | 9.24M |
Cash Flow | ||||||
| Free Cash Flow | -9.48M | -13.19M | -18.91M | -19.96M | -22.36M | -10.32M |
| Operating Cash Flow | -9.48M | -13.14M | -18.23M | -19.63M | -19.18M | -8.49M |
| Investing Cash Flow | 52.00K | -2.00K | -468.00K | -603.00K | -3.33M | -1.83M |
| Financing Cash Flow | 8.09M | 13.17M | 13.77M | 17.26M | 29.71M | 8.98M |
Scandinavian ChemoTech AB Class B Technical Analysis
Positive
4.90
Price Trends
4.75
Positive
3.42
Positive
2.41
Positive
Market Momentum
-0.07
Positive
45.36
Neutral
31.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CMOTEC.B, the sentiment is Positive. The current price of 4.9 is below the 20-day moving average (MA) of 5.88, above the 50-day MA of 4.75, and above the 200-day MA of 2.41, indicating a neutral trend. The MACD of -0.07 indicates Positive momentum. The RSI at 45.36 is Neutral, neither overbought nor oversold. The STOCH value of 31.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CMOTEC.B.
Scandinavian ChemoTech AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | kr116.25M | ― | -380.40% | ― | 113.59% | 54.12% | |
52 Neutral | €50.30M | ― | ― | 8.06% | -94.12% | -25.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | kr57.15M | ― | -97.11% | ― | -13.08% | 32.78% | |
41 Neutral | kr71.08M | ― | -65.12% | ― | ― | 42.09% | |
39 Underperform | kr73.86M | ― | -136.44% | ― | -30.49% | -242.26% |
* Healthcare Sector Average
SE:CMOTEC.B
Scandinavian ChemoTech AB Class B
4.90
2.97
153.89%
SE:2CUREX
2cureX AB
1.54
1.00
185.19%
SE:ONCOZ
OncoZenge AB
5.60
-4.86
-46.46%
SE:EXPRS2
ExpreS2ion Biotech Holding AB
21.40
-13.16
-38.08%
SE:LARK
CombiGene AB
2.53
0.38
17.57%
SE:SPRINT
Sprint Bioscience AB
0.70
-1.06
-60.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.